City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  54  Clinical trial(s) found  (Page 1 of 3 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for Brain and Nervous System Cancer:
COH Protocol Number: 16216 ClinicalTrials.gov Number: NCT02844439

Principal Investigator: Jana Portnow, MD
Sponsor: Industrial

Title:  A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients with Recurrent Glioblastoma

COH Protocol Number: 16190 ClinicalTrials.gov Number: NCT02402244

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG APEC14B1: The Project: Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

COH Protocol Number: 16169

Principal Investigator: Jana Portnow, MD
Sponsor: Institutional

Title:  Single Subject Protocol for SS- Treatment Use of Neratinib for EGFR-positive High-grade Glioma

COH Protocol Number: 16114

Principal Investigator: Jana Portnow, MD
Sponsor: Institutional

Title:  Single Subject Protocol for PC for Treatment of Rindopepimut (CDX-110)

COH Protocol Number: 16062 ClinicalTrials.gov Number: NCT02546102

Principal Investigator: Jana Portnow, MD
Sponsor: Industrial

Title:  A Phase III Randomized Double-blind, Controlled Study of ICT-107 with Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy

COH Protocol Number: 15448

Principal Investigator: Jana Portnow, MD
Sponsor: Institutional

Title:  Single Subject Protocol for SA for Treatment with Rindopepimut (CDX-110) and Bevacizumab

COH Protocol Number: 15331 ClinicalTrials.gov Number: NCT02308020

Principal Investigator: Jana Portnow, MD
Sponsor: Industrial

Title:  A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma

COH Protocol Number: 14221 ClinicalTrials.gov Number: NCT02176967

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

COH Protocol Number: 14108 ClinicalTrials.gov Number: NCT02192359

Principal Investigator: Jana Portnow, MD
Sponsor: NCI Approved External Peer Review

Title:  A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas

COH Protocol Number: 13401 ClinicalTrials.gov Number: NCT02015819

Principal Investigator: Jana Portnow, MD
Sponsor: Institutional

Title:  A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination with Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas

COH Protocol Number: 13384 ClinicalTrials.gov Number: NCT02208362

Principal Investigator: Behnam Badie, MD
Sponsor: Institutional

Title:  Phase I Study of Cellular Immunotherapy Using Central Memory Enriched T Cells Lentivirally Transduced to Express an IL13Ra2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients with Recurrent/Refractory Malignant Glioma

COH Protocol Number: 13140 ClinicalTrials.gov Number: NCT01096368

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG ACNS0831:Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma ages 1-21 years

COH Protocol Number: 01094

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG ANBL00B1: Neuroblastoma Biology Studies

The following studies are available for many cancer types, including Brain and Nervous System Cancer:
COH Protocol Number: 16219

Principal Investigator: Jeffrey Weitzel, MD
Sponsor: NCI Approved External Peer Review

Title:  Understanding How Clients Make Meaning of Their Variants of Uncertain Significance in the Age of Multi-Gene Panel Testing for Cancer Susceptibility

COH Protocol Number: 16124 ClinicalTrials.gov Number: NCT02717507

Principal Investigator: Saro Armenian, DO
Sponsor: Cooperative Group

Title:  COG ALTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

COH Protocol Number: 15434 ClinicalTrials.gov Number: NCT02465060

Principal Investigator: Karen Reckamp, MD
Sponsor: Cooperative Group

Title:  ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)

COH Protocol Number: 15320

Principal Investigator: Vincent Chung, MD
Sponsor: Institutional

Title:  The Total Cancer Care Protocol: A Lifetime Partnership with Patients of the City of Hope

COH Protocol Number: 15293 ClinicalTrials.gov Number: NCT02568267

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

COH Protocol Number: 15268 ClinicalTrials.gov Number: NCT02628067

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)

COH Protocol Number: 15259

Principal Investigator: Matthew Loscalzo, MSW
Sponsor: Institutional

Title:  Validation of 'You, Your Family and COH Are a Team' Core Questions for the Biopsychosocial Distress Screening

COH Protocol Number: 15236 ClinicalTrials.gov Number: NCT02535312

Principal Investigator: Marianna Koczywas, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-76, NCI#9837: Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Cisplatin and Pemetrexed

COH Protocol Number: 15233 ClinicalTrials.gov Number: NCT02091141

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab Erlotinib, Vemurafenib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive or Response to One of these Agents

COH Protocol Number: 15219 ClinicalTrials.gov Number: NCT02383212

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A First-in-Human Study of Repeat Dosing with REGN2810, A Monoclonal, Fully Human Antibody to Programmed Death-1 (PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies

COH Protocol Number: 15213 ClinicalTrials.gov Number: NCT02453620

Principal Investigator: George Somlo, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-83, NCI#9844: A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors

COH Protocol Number: 15173 ClinicalTrials.gov Number: NCT02482168

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  Phase 1 Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Subjects with Solid Tumors

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.